Skip to main content
SpringerLink
Log in

Myeloproliferative Neoplasms

  • Reference work entry
  • First Online:
Geriatric Diseases

  • 1559 Accesses

Abstract

Myeloproliferative neoplasms (MPNs) formerly known as chronic myeloproliferative disorders are clonal haemopoietic stem cell disorders characterised by excessive production of mature blood cells. The classic MPNs are polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF) (Phi-negative) and chronic myelogenous leukaemia (CML), and the central role of protein tyrosine kinases in their pathogenesis have been identified. The hallmark for diagnosis of CML is demonstrating the presence of Philadelphia (Ph) chromosome in the bone marrow cells. This review provides an overview of the myeloproliferative neoplasms, their classification and their management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 379.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukaemia. 2008;22(10):1813–7.

    Article  CAS  Google Scholar 

  2. Vainchenker W, Delhommeau F, Constntinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723–1735.

    Article  CAS  PubMed  Google Scholar 

  3. Kico JM, Vij R, Kreisel FH, Hassan, Frater JL. Molecular pathology of myeloproliferative neoplasms. Am J Clin Pathol. 2010:133:602–615. https://doi.org/10.1309/AJCPPPZIWFVGNE4A.

  4. Wadleigh M, Teferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organisation criteria. Int J Hamatol. 2010;91(2(:174–9.

    Article  Google Scholar 

  5. Schmidt AE, Oh ST. Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Am J Clin Pathol. 2012;138(1):12–9.

    Article  CAS  PubMed  Google Scholar 

  6. Groffen J, Stephenson JR, Heisterkamp A, de Klein A, Bartram CR, Grosweld G. Philadelphia chromosome breakpoints are clustered on a limited region bar on chromosome 22. Cell. 1984:36(1):93–99.

    Article  CAS  PubMed  Google Scholar 

  7. Mascarenhas J, Mughal TI, Verstosek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26): 4399–413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasm: role and mechanisms of chronic inflammation. Mediators of Inflammation https://doi.org/10.1155/2015/145293.

  9. Kralovics R, Passmonti F, Buser AS, Teo SS, Tiedt LR, Passweg JR, et al. A gain-of-function mutation of JAK2in myeloproliferative disorder. NEJM. 2005;356(17):1779–1798.

    Article  Google Scholar 

  10. Schnittger S, Bacher U, Haferlach C, Dengler R, Krober A, Kern W, et al. Characterization of 35 new cases with four different MPL to 515 mutations in ET or PMF. Haematologica. 2009;94(1):141–144.

    Article  PubMed  Google Scholar 

  11. Nangalia J, Massie CE, Baxter EJ, Nice Fl, Gundem G, Wedge DC, et al. Somatic CLAR mutation in myeloproliferative neoplasms with nonmutated AK2. NEJM. 2013;369(25):2391–2405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Michiels JJ, Berneman Z, Schroyens W, De Raeve H. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 150 to Vainchenker 2005 and beyond. Acta Haematol. 2015;133(1):36–5.

    Article  PubMed  Google Scholar 

  13. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome –positive leukaemias from basic and molecular therapeutics. Ann Intern Med. 2003;138:819–30.

    Article  CAS  PubMed  Google Scholar 

  14. Goldman JM, Melo TW. The molecular biology of chronic myeloid leukaemia. Blood. 2003;96(10).

    Google Scholar 

  15. Oscier DG. Atypical chronic myeloid leukaemia: a distinct clinical entity related to the myelodysplastic syndrome. Haematol. 1996;92 (3):582–586.

    Article  CAS  Google Scholar 

  16. Kurzrock R, Bueso-Ramos CE, Kantarijian H, Freireich E, Tucker SL, Sicilliano M, et al. BCR rearrangement –negative chronic myelogenous leukaemia. Clin Oncol. 2001;19(11):2915–26.

    Article  CAS  Google Scholar 

  17. Jabbour E, Cortes J, Kantarjian H. Long term outcomes in the second –line treatment of chronic myeloid leukaemia: a review of tyrosine kinase inhibitors. Cancer. 2011;117(5):897–906.

    Article  PubMed  Google Scholar 

  18. Gibson J, Iland HJ, Larsen SR, Brown CMS, Joshua DE. Leukaemias into the 21st century-part 2: the chronic leukaemia. Int Med J. 2013; 43: 484–494.

    Article  CAS  Google Scholar 

  19. Wong SF, Mirshahidi H. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Ann Pharmather. 2011;45(6):787–97.

    Article  CAS  Google Scholar 

  20. Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long term survival estimates for Imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed Chronic-phase chronic myeloid leukaemia Cancer. 2004;101:2584–92.

    Article  CAS  PubMed  Google Scholar 

  21. Finazzi G, Barbul T. How I treat patients with polycythaemia vera. Blood. 2007;109:no. 12 5104–5111.

    Article  CAS  PubMed  Google Scholar 

  22. Besa GC, Woermann V. Polycythaemia vera. http://www.emedicine.com/MED/topic1864.htm.

  23. Saini KS, Patnaik MM, Tefferi A. Polycythaemia associated pruritus and its management. Eur J Clin Invest. 2010;40(4):828–34.

    Article  PubMed  Google Scholar 

  24. Patel RK, Lea N, Heneghan A, Westwood NB, Milojkovic D, Thanigalkumar M, et al. Prevalence of the activating JAL2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031–2038.

    Article  CAS  PubMed  Google Scholar 

  25. Fizzani G, Barbul T. Expertise-based management in essential thrombocythemia and polycythaemia vera. Cancer J. 2007;13(6):372–6.

    Article  Google Scholar 

  26. Mossuz P, Girodon F, Donnard M, Lattger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89(10):1194–8.

    CAS  PubMed  Google Scholar 

  27. Dessypris EN. Abnormal haematocrit in Internal Medicine Editor –in-Chief JW Stein Fifth edition, 1998, p 586, Mosby Inc, St Louis, Missouri.

    Google Scholar 

  28. Campbell PI, Green AR. The myeloproliferative disorders. NEJM. 2006;355:2452–2466.

    Article  CAS  PubMed  Google Scholar 

  29. Tefferi A, Barbul T. bcc/abl negative classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80:1220–1232.

    Article  PubMed  Google Scholar 

  30. Tefferi A. Polycythaemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003;76:174–194.

    Article  Google Scholar 

  31. Messinezy M, Pearson TC. ABC of clinical haematology. Clinical Review. BMJ. 1997;34:587.

    Article  Google Scholar 

  32. Penninga EI, Bjerrum OW. Polycythaemia vera and thrombocythaemia: current treatment and strategies. Drugs. 2006;66(17):2173–87.

    Article  CAS  PubMed  Google Scholar 

  33. Griesshammer M, Langer C. Pharmacotherapy of essential thrombocythaemia: economic consideration. Summary: Expert opinion in Pharmacotherapy. 2003;4:1499–1505.

    CAS  Google Scholar 

  34. Tefferi A. Myelofibrosis and myeloid metaplasia. NEJM. 2000;342(17):1255–1264.

    Article  CAS  PubMed  Google Scholar 

  35. Kvasnicka HM, Thiele J, Werden C, et al. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:707–719.

    Article  Google Scholar 

  36. Manoharan A. Myelofibrosis: Prognostic factors and treatment. Annotation. Brit J Haematol. 1988; 69: 295–298.

    Article  CAS  Google Scholar 

  37. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, et al. Cytogenetic abnormalities and their prognosis in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997;98:96–102.

    Article  CAS  PubMed  Google Scholar 

  38. Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105:618–625.

    Article  CAS  PubMed  Google Scholar 

  39. Bazargan A., Tam C. Janus kinase inhibitors in myeloproliferative neoplasms. Aust Prescriber. 2014;37:161–162.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Sydney, Westmead Clinical School, Westmead, NSW, Australia

    Nages Nagaratnam & Kujan Nagaratnam

  2. Rehabilitation and Aged Care Service, Blacktown-Mt Druitt Hospital, Mount Druitt, NSW, Australia

    Gary Cheuk

Authors
  1. Nages Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kujan Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Cheuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2018). Myeloproliferative Neoplasms. In: Geriatric Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-33434-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33434-9_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33433-2

  • Online ISBN: 978-3-319-33434-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation